title: Sequential changes in pathophysiology of systemic inflammatory response in a disseminated neonatal herpes simplex virus (HSV) infection.
abstract: BACKGROUND
  Disseminated neonatal herpes simplex virus (HSV) infection causes a typical systemic inflammatory response syndrome and has a high mortality rate. However, the validity of anti-inflammatory intervention against this condition remains unknown.
  
  
  OBJECTIVE
  We sought to demonstrate the sequential changes in the pathophysiology of disseminated neonatal HSV infections.
  
  
  METHODS
  The HSV serum copy number as well as high-mobility group box 1 (HMGB1) and cytochrome c concentrations, which predict the severity and mortality rate of sepsis, were sequentially evaluated in a patient with disseminated neonatal HSV infection caused by HSV-2.
  
  
  RESULTS
  As the patient presented with evidence of hyper-inflammation and severe illness, we empirically undertook anti-inflammatory intervention that included the administration of prednisolone, high-dose immunoglobulin, and blood exchange therapy in addition to high-dose acyclovir (ACV) therapy. The patient survived without significant neurological sequela. We found that (1) the serum concentrations of both HMGB1 and cytochrome c were extremely high, (2) temporal increases in these biomarkers were observed after admission, and (3) interestingly, the increase in HMGB1 level preceded that of cytochrome c. These results suggested that the pathophysiology of this condition changed sequentially in a dramatic manner, and the timing of our anti-inflammatory intervention was prior to the transition of pathological status from hyper-inflammation to massive apoptosis.
  
  
  CONCLUSIONS
  Anti-inflammatory intervention may only be effective if it is undertaken during the early phase of disseminated neonatal HSV infections.
authors.affiliation: Department of Pediatrics, Asahikawa Medical University, Hokkaido, Japan. ntsune5p@asahikawa-med.ac.jp
authors.forename: Tsunehisa
authors.initials: T
authors.lastname: Nagamori
authors.forename: Shin
authors.initials: S
authors.lastname: Koyano
authors.forename: Yoko
authors.initials: Y
authors.lastname: Asai
authors.forename: Fumikatsu
authors.initials: F
authors.lastname: Nohara
authors.forename: Toshio
authors.initials: T
authors.lastname: Okamoto
authors.forename: Ken
authors.initials: K
authors.lastname: Nagaya
authors.forename: Tokitsugi
authors.initials: T
authors.lastname: Hayashi
authors.forename: Yurika
authors.initials: Y
authors.lastname: Miura
authors.forename: Naoya
authors.initials: N
authors.lastname: Tsuda
authors.forename: Kenichi
authors.initials: K
authors.lastname: Iseki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Azuma
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D045304:Cytochromes c / Q000097:blood; D004279:DNA, Viral / Q000097:blood / Q000134:cerebrospinal fluid; D024243:HMGB1 Protein / Q000097:blood; D006561:Herpes Simplex / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D019562:Viral Load; D014766:Viremia / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D000893:Anti-Inflammatory Agents; D000998:Antiviral Agents; D004279:DNA, Viral; D024243:HMGB1 Protein; D045304:Cytochromes c; D000212:Acyclovir